The US IPO Index has plummeted 51% year-to-date, in the IPO market’s sharpest sell-off since at least the 2008 Global Financial Crisis. Of the 397 traditional IPOs in 2021, only 12% are trading above issue. Rampant speculation and near-zero interest rates ...read more
Updated Monday, 12/14.
Six IPOs and five SPACs are scheduled to raise $2.8 billion in the week ahead as the IPO market starts to slow down before the holidays.
Bargain e-commerce platform Wish (WISH) plans to raise $1.1 billion at a $16.4 billion market ...read more
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals (OLMA), which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an...read more
Maravai LifeSciences, which provides genetic products and testing services for drug development and research, raised $1.6 billion by offering 60 million shares at $27, the high end of the $24 to $27 range.
As a supplier of oligonucleotides and products ...read more
These IPOs have outperformed during the biggest sell-off in over a decade
The US IPO Index has plummeted 51% year-to-date, in the IPO market’s sharpest sell-off since at least the 2008 Global Financial Crisis. Of the 397 traditional IPOs in 2021, only 12% are trading above issue. Rampant speculation and near-zero interest rates ...read more
US IPO Week Ahead: The IPO market makes a holiday WISH in a 6 IPO week
Updated Monday, 12/14. Six IPOs and five SPACs are scheduled to raise $2.8 billion in the week ahead as the IPO market starts to slow down before the holidays. Bargain e-commerce platform Wish (WISH) plans to raise $1.1 billion at a $16.4 billion market ...read more
US IPO Weekly Recap: Breast cancer biotech pops 158% in a 6 IPO week
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals (OLMA), which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an...read more
Genetic products supplier Maravai LifeSciences prices upsized IPO at $27 high end
Maravai LifeSciences, which provides genetic products and testing services for drug development and research, raised $1.6 billion by offering 60 million shares at $27, the high end of the $24 to $27 range. As a supplier of oligonucleotides and products ...read more